<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234114</url>
  </required_header>
  <id_info>
    <org_study_id>007</org_study_id>
    <nct_id>NCT03234114</nct_id>
  </id_info>
  <brief_title>Optimal Antithrombotic Therapy for ACS Patients Concomitant AF Undergoing New Generation DES Implantation</brief_title>
  <official_title>Optimal Antithrombotic Therapy for Acute Coronary Syndrome Patients Concomitant Atrial Fibrillation Undergoing New Generation Drug Eluting Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a multi-centered randomized clinical trial (RCT) which will enroll 3742 patients with
      acute coronary syndrome (ACS) concomitant non-valvular atrial fibrillation (NVAF) and
      undergoing new generation drug eluting stent (DES) implantation at 59 centers nationwide in
      China and contains two sub-studies.

      In the OPTIMA-1 sub-study, 2272 subjects who choose warfarin as anticoagulant will randomly
      receive triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg
      od and aspirin 100 mg od) for 1 month or 6 months in a 1:1 ratio then quit aspirin till 12
      months after percutaneous coronary intervention (PCI). The primary endpoint of the OPTIMA-1
      is a composite of cardiovascular death, myocardial infarction, ischemic stroke, systemic
      thromboembolism and unplanned revascularization up to 12 months; the major secondary endpoint
      is the International Society of Thrombosis and Hemostasis (ISTH) major bleeding or clinically
      relevant non-major bleeding (CRNMB).

      In the OPTIMA-2 sub-study, 1470 subjects who prefer dabigatran will be randomly assigned in a
      1:1 ratio to a dual antithrombotic therapy of dabigatran 110 mg twice daily with ticagrelor
      90 mg twice daily or with clopidogrel 75 mg od for 12 months after PCI. The primary safety
      endpoint of the OPTIMA-2 is ISTH major bleeding or CRNMB at 12 months; the primary efficacy
      endpoint is a composite of cardiovascular death, myocardial infarction, ischemic stroke,
      systemic thromboembolism and unplanned revascularization.

      Other secondary endpoints comprise death (cardiovascular, non- cardiovascular), MI (fatal or
      non-fatal, Q-wave or non-Q-wave), unplanned revascularization (target or non-target vessel,
      target or non-target lesion), stent thrombosis (possible, probable, definite), stroke
      (hemorrhage or ischemic), all bleeding (ISTH and BARC criteria) and net adverse events.

      All endpoints will be collected and compared between subgroups and sub-studies during
      hospitalization and in 1 month (± 7 days), 6 months (± 7 days) and 12 months (± 7 days) for
      office visits and in 2 weeks (± 7 days), 2 months (± 7 days) and 3 months (± 7 days) for
      phone call visits.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary endpoint of OPTIMAL-1</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>A composite of cardiovascular death, myocardial infarction, ischemic stroke, systemic thromboembolism and unplanned revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary safety endpoint of OPTIMAL-2</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>ISTH major bleeding or CRNMB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary efficacy endpoint of OPTIMAL-2</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>A composite of cardiovascular death, myocardial infarction, ischemic stroke, systemic thromboembolism and unplanned revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major secondary endpoint of OPTIMAL-1</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>Major bleeding or clinically relevant non-major bleeding assessed by the ISTH definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary endpoints of OPTIMAL-1/2</measure>
    <time_frame>Up to 12 months (± 7 days) after inclusion</time_frame>
    <description>Death (cardiovascular, non- cardiovascular), MI (fatal or non-fatal, Q-wave or non-Q-wave), unplanned revascularization (target or non-target vessel, target or non-target lesion), stent thrombosis (possible, probable, definite), stroke (hemorrhage or ischemic), all bleeding (ISTH and BARC criteria) and net adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3742</enrollment>
  <condition>Acute Coronary Syndrome (ACS)</condition>
  <condition>Non-valvular Atrial Fibrillation (NVAF)</condition>
  <arm_group>
    <arm_group_label>1-month TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized control group in the OPTIMAL-1 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 1 month (30 days) then quit aspirin till 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6-month TT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized control group in the OPTIMAL-1 substudy; Triple antithrombotic therapy (warfarin with targeted INR 2.0-3.0, clopidogrel 75 mg od and aspirin 100 mg od) for 6 months (180 days）then quit aspirin till 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-month DT-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized control group in the OPTIMAL-2 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with clopidogrel 75 mg qd for 12 months after PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12-month DT-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized control group in the OPTIMAL-2 substudy; Dual antithrombotic therapy including dabigatran 110 mg b.i.d. with ticagrelor 90 mg b.i.d for 12 months after PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triple antithrombotic therapy</intervention_name>
    <description>Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg per day (Bayer, Germany) and clopidogrel 75 mg per day (Sanofi, France)</description>
    <arm_group_label>1-month TT</arm_group_label>
    <arm_group_label>6-month TT</arm_group_label>
    <other_name>TT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual antithrombotc therapy</intervention_name>
    <description>Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain) or clopidogrel 75 mg per day (Sanofi, France)</description>
    <arm_group_label>12-month DT-1</arm_group_label>
    <arm_group_label>12-month DT-2</arm_group_label>
    <other_name>DT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years;

          -  ACS patients concomitant non-valvular AF (paroxysmal, persistent and permanent)
             underwent PCI and new-generation DES implantation;

          -  CHA2DS2-VASc score ≥ 2;

          -  Acceptable risk of bleeding at the discretion of the researchers (e.g. HAS-BLED score
             ≤ 2)

          -  Consent to participate in the trial

        Exclusion Criteria:

          -  DES implanted in the left main coronary artery

          -  Cardiogenic shock or Killip III-IV

          -  STEMI patients with malignant arrhythmias or underwent electrodefibrillation or CPR or
             with cardiac mechanical complications (heart rupture, ventricular septal perforation,
             nipple muscle fracture, etc.)

          -  History of gastrointestinal or intracranial hemorrhage; active bleeding, trauma or
             major surgery within one month; suspected or diagnosed aortic dissection

          -  Ischemic stroke with limb dysfunction or dysphasia

          -  Known allergy or intolerance to the study medications: warfarin, clopidogrel, aspirin,
             dabigatran, ticagrelor and heparin

          -  Participating in other ongoing trials

          -  Planned surgery in 12 months requiring to withdraw the antiplatelet agents

          -  Planned RFCA or left atrial appendage occlusion in the next 12m

          -  Abnormal liver or kidney function (ALT ≥ 3 ULN; estimated CrCl &lt; 30 ml/min calculated
             by Cockcroft-Gault equation); diagnosed liver cirrhosis

          -  Hematological disease with bleeding tendency; hemoglobin &lt; 100 g/L, platelet count &lt;
             100 × 10^9 /L

          -  Malignancies or life expectancy less than 1 year

          -  Pregnant (present, suspected, or planned) or lactating woman

          -  Patients who are taking drugs which may interact with study agents, such as
             miconazole, ketoconazole, fluconazole, voriconazole, itraconazole, posaconazole,
             efinaconazole, and rifampicin, etc.

          -  Patients with any other conditions that may not be suitable to participate in the
             trial at the discretion of the researchers.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chunjian Li, Dr, PhD</last_name>
    <phone>+86-13701465229</phone>
    <email>drcjli@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoxuan Gong, MD</last_name>
    <phone>+86-18851727059</phone>
    <email>xiaoxuangong@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuming Zhang, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yi Chai, M.D.</last_name>
      <phone>+86-25-83718836</phone>
      <phone_ext>6360</phone_ext>
      <email>jsphkj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Chunjian Li, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoxuan Gong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 25, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Dr., MD, Ph.D, Director of CCU Ward</investigator_title>
  </responsible_party>
  <keyword>new generation drug eluting stent (DES)</keyword>
  <keyword>antithrombotic therapy</keyword>
  <keyword>randomized clinical trial (RCT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

